Document is current
Any future updates will be listed below
-
Authors
Mair, Florian https://orcid.org/0000-0001-6732-5449
Erickson, Jami R. https://orcid.org/0000-0002-4549-5217
Frutoso, Marie https://orcid.org/0000-0002-7848-1049
Konecny, Andrew J.
Greene, Evan
Voillet, Valentin
Maurice, Nicholas J. https://orcid.org/0000-0002-2667-472X
Rongvaux, Anthony https://orcid.org/0000-0001-7142-6533
Dixon, Douglas https://orcid.org/0000-0003-0911-3717
Barber, Brittany
Gottardo, Raphael
Prlic, Martin https://orcid.org/0000-0002-0685-9321
- License Information
-
More Information
Article History
Received: 23 March 2021
Accepted: 1 April 2022
First Online: 11 May 2022
Competing interests
: Part of the single-cell sequencing experiments was supported with reagents received from BD Biosciences and Illumina. BD Biosciences and Illumina were not involved in data analysis and interpretation. R.G. has received speaker fees from Illumina and Fluidigm and support from Juno Therapeutics and Janssen Pharma, has consulted for Takeda Vaccines, Juno Therapeutics and Infotech Soft, and has ownership interest in Modulus Therapeutics. E.G. and R.G. declare ownership interest in Ozette Technologies. F.M., J.R.E. and M.P. hold the related patent <i>Specific Targeting of Tumor-infiltrating regulatory T cells (Tregs) using ICOS and IL-1R1</i> (US patent no. 63/092957).
